Beta Bionics, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
The following table summarizes the facilities leased as of December 31, 2025, including the location and size of each principal facility and their designated use. We believe that these facilities are sufficient to meet our current and anticipated future needs and that suitable additional alternative spaces would be available in the future on commercially reasonable terms if deemed necessary.
| Location | Primary Use | Approximate Square Footage | Lease Expiration Year |
|---|---|---|---|
| Concord, Massachusetts | General and Administrative, R&D | 13,035 | 2026 |
| Cincinnati, Ohio | Pharmacy and Sales | 1,524 | 2026 |
| San Diego California | General and Administrative, Technical Support | 7,881 | 2027 |
| San Diego California | General and Administrative, R&D | 12,467 | 2028 |
| Irvine, California | General and Administrative, R&D, Manufacturing, Warehouse | 50,020 | 2032 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.